Treating triple-negative breast cancer by repurposing old drugs for diabetes and rare blood disorder

Triple-negative breast cancer patients lack three common markers—estrogen, progesterone and HER2—making them unresponsive to targeted therapies. A team led by University of Chicago scientists may have found a new option for these patients, and it's one that involves combining two old FDA-approved drugs for diabetes and porphyria, a rare disorder marked by a lack of heme, a substance in blood that's essential for oxygen transport.
Read more...

;